Biotech Investing
(Editor's note) The evolving geopolitical landscape in the Middle East warrants close attention from market participants. Elevated volatility may pressure near-term returns; however, it can also open selective opportunities for investors with appropriate risk tolerance and a long-term perspective. Above all, we stand in solidarity with those directly
Oncology
Three months ago, we called INAB a "tier-one scientific innovator trapped in a tier-four financial vehicle." Since then, the company has raised $20 million, appointed a new President, and quietly unveiled what may be its most valuable asset. Here's what's changed — and what hasn't.
(Editor's note : I'm releasing the Week 4 Scanner a bit early, as I'm currently tied up with a new project at work. A quick heads-up on something not covered in this week’s issue: MoonLake Immunotherapeutics ($MLTX) is hosting its Investor Day on February
(Editor's note) I would like to remind readers that this scanner is designed to provide preliminary leads and spark ideas for further analysis. While our platform leverages historical data, machine learning, and AI-driven insights, predictive modeling is inherently uncertain. Please conduct thorough independent research before making any investment
I apologize for the delay in providing this week’s scanner result due to my travel commitments. Small-cap biotech continues its brutal selloff as sector rotation accelerates into large-cap pharma. The XBI closed the week down 3.2%, extending its drawdown to -18% year-to-date as risk appetite evaporates ahead of
The biotech sector is entering February with mixed signals. XBI traded at $120.23, down 1.06% on the day, pulling back from recent highs near $131. After a strong 2025 finish that saw the equal-weighted biotech ETF surge nearly 37% year-to-date by December, January 2026 has brought profit-taking and
The biotech sector enters Q1 2026 with renewed optimism as XBI hovers around $120-131, digesting strong 2025 gains that saw the equal-weight ETF outperform the broader health sector. Dealmaking chatter continues to drive sentiment, with Mizuho analysts pointing to sustained M&A activity as big pharma fills pipelines through
AI
Last week's 44th annual J.P. Morgan Healthcare Conference closed with a whimper rather than a bang. The industry's premier gathering—where mega-deals typically set the tone for the year—delivered what prominent biotech investor Brad Loncar called "the slowest JPM for news in a
AI
Takeover Rumors Swirl Around Revolution Medicines and Abivax as Industry Giants Hunt for Blockbusters The 44th Annual J.P. Morgan Healthcare Conference officially begins today, January 12, 2026, setting the stage for what analysts are already calling a "banner year" for biopharma M&A. The dealmaking atmosphere
Finding Undervalued Biotechs via Thorough Investigation and Sharing Tips
And it wasn't a very good idea!
After a jam-packed December 2025, we enter the second week of 2026 with a sharply divided biotech market. While the XBI struggles to find its footing, our scanner has identified a distinct bifurcation: a cluster of “Pressure Cooker” setups—micro-caps with shrinking cash runways colliding with near-term data—versus well-capitalized
As we approach the end of the year, I want to take a moment to wish all our subscribers a very Merry Christmas and a Happy New Year. It has been a year of navigating the volatile biotech markets together, and I truly appreciate the community of independent-minded investors we&
The XBI sits at $123 near its 52-week high of $125.87—a 27% climb from April lows that's rewarded risk-takers but now leaves less margin for error. With year-end tax selling and portfolio rebalancing underway, the question isn't whether biotech is "back" but
Two emerging biotechs just became the most attractive acquisition targets in obesity after releasing game-changing Phase 1 and Phase 2 data on December 8th.
Black Friday sale extended to biotechs, with numerous attractive companies trading at bargain prices. Outcome of last week's scanner revealed a significant surprise, especially with CAPR despite ongoing skepticism about the data’s credibility. JANX, as discussed in my recent article, disappointed investors. However, this is the nature
The $1 trillion battleground where pharma giants and scrappy biotechs are fighting for supremacy — and why the real winners may be patients who couldn't afford these drugs before.
In the high-stakes world of biotechnology, "good" is often not enough when the market is pricing in "perfection." Yesterday, Janux Therapeutics ($JANX) released updated Phase 1 data that triggered a sharp >40% sell-off. The market’s simplistic algorithm—"No massive beat on the headline
The XBI just logged a +10.72% gain over 21 days—and the beaten-down clinical-stage names are stirring. This week's scanner combed through 250+ catalyst events expected within 10-45 days. What jumps off the screen? Eight companies currently trade below their cash balances. The market has essentially written
Data-driven biotech investing: Biostockinfo reveals how clinical catalysts, anticipation run-ups and Breakthrough Therapy designations create alpha for independent retail investors.
I apologize for the delay in this week’s AI Scanner. I’ve been working on using newly updated Gemini 3.0, which was supposed to be superior. However, the results were mixed, and it took some time to debug the system. This AI Scanner is still work in progress,
Is this a value trap headed for dilution and oblivion—or a deeply mispriced recovery play for investors who can live with binary risk?
